Premium
The significance of resections for residual masses after chemotherapy in metastatic testicular tumors
Author(s) -
Suzuki Kenichi,
Orikasa Seiichi,
Hoshi Senji,
Yoshikawa Kazuyuki,
Saito Seiichi,
Ohyama Chikara,
Sato Makoto,
Kawamura Sadahumi,
Numahata Kenji,
Ito Akihiro,
Tokuyama Satoru
Publication year - 1999
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.1999.00062.x
Subject(s) - medicine , seminoma , testicular cancer , chemotherapy , stage (stratigraphy) , teratoma , cancer , germ cell tumors , surgery , metastasis , oncology , paleontology , biology
Background : After chemotherapy for metastatic testicular tumors, masses may remain, often in the metastatic sites. This study analyses the role of resections for the residual masses. Methods : Seventy‐seven patients with advanced (stage II, III) testicular tumors were treated. Of these, 38 patients, including eight with seminoma and 30 patients with non‐seminomatous germ cell tumors, underwent resection of residual masses after chemotherapy and have been followed for a median of 41.5 months (range 2–138) after the resection. Results : Residual masses were necrosis/fibrosis in 19 patients, mature teratoma in 11 and cancer in eight. The ratio of cancer in stage III (41.2%) was significantly higher than that in stage II (4.8%). Ten of 38 (26.3%) patients experienced recurrences in sites other than the resected sites, and five of 10 patients have died of cancer. Most recurrences (80%) occurred within two years. Recurrences after resection were detected in 4.8% of stage II patients, 52.9% of stage III, 16.7% of necrosis/fibrosis and mature teratoma, and 62.5% of cancer. The survival rate of patients with cancer was significantly lower in spite of adjuvant chemotherapy after surgery. Conclusions : Resection for residual masses after chemotherapy in metastatic testicular tumors was useful in confirming the tissue and in controlling the metastatic sites. Recurrences were often found in patients with cancer in the residual mass and the prognosis of patients with cancer was poor, therefore the development of more effective therapy for patients with cancer is required to improve the prognosis.